Search

Author/Creator Webster, N.

5. P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. (23rd June 2022)

Authors:
Rawstron, A.; Webster, N.; Pitchford, A.; Dalal, S.; Bloor, A.; de Tute, R.; Hockaday, A.; Jackson, S.; Cairns, D.; Greatorex, N.; Allsup, D.; Munir, T.; Hillmen, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
571
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. (23rd June 2022)

Authors:
Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗